Analysis: Most Commercially Available CBD Products Mislabeled, Make Misleading Claims
“These findings highlight the need for proper regulatory oversight of cannabinoid-containing products to ensure quality assurance and deter misleading or unfounded health claims in product marketing,” the study’s authors concluded. The post Analysis: Most Commercially Available CBD Products Mislabeled, Make Misleading Claims appeared first on NORML.
